- Home
- NEWS
- REGIONAL
- THIS WEEK'S PAPER
- BLOGS
- Multimedia
- OPINION
- A&E
- LISTS
- PEOPLE
- EVENTS
- Classifieds
- Subscribe
Pharmaceutical
EU approves Lilly's weekly diabetes drug Bydureon
June 21, 2011
Associated PressEuropean Union regulators have approved the first once-per-week diabetes medication, the companies that developed the drug
said Tuesday.
MoreMedco deal loses its luster
June 13, 2011
J.K. WallNew Jersey-based Medco has hired just 430 workers in Whitestown—far short of its commitment of 1,400 by 2012—and its business
trends suggest the company is shrinking, not growing.
MoreLilly enters collaboration deal with Swiss company
June 9, 2011
Associated PressDrugmaker Eli Lilly and Co. has signed a deal with Swiss company Synthes Inc. to co-promote the bone drug Forteo and develop
other potential orthopedic treatments.
MoreDrug industry outlook negative through 2012, Moody’s says
June 8, 2011
Bloomberg NewsEarnings growth will continue to slow in 2011 for most of the industry’s biggest companies, analyst predicts.
MoreMedco may seek acquisition with biggest contract imperiled
June 7, 2011
Bloomberg NewsMedco Health Solutions Inc., which operates a $140 million automated pharmacy and distribution center in Whitestown, has lost
$3.5 billion in contracts since March.
MoreLilly licenses Xigris rights to new biotech firm
May 23, 2011
J.K. WallEli Lilly and Co. has agreed to license the U.S. marketing rights of its slow-selling sepsis drug Xigris to a newly created
local biotech company called BioCritica that will seek to reinvigorate sales of the medication.
MorePrescription drug abuse growing problem in Indiana
May 16, 2011
Associated PressPrescription drugs are playing an increasing role in the drug-related crimes that are filling up Indiana's prisons, prison
officials and prosecutors said.
MoreAmylin sues Lilly over drug development deal
May 16, 2011
Associated PressAmylin Pharmaceuticals Inc. said Monday it filed a lawsuit against Eli Lilly and Co., accusing the larger drugmaker of breaking
their commercialization deal for diabetes drugs by teaming with the German company Boehringer Ingelheim to develop and sell
a competing product.
MoreLilly drug to detect Alzheimer’s criticized by consumer group
May 11, 2011
Bloomberg NewsEli Lilly and Co.’s Amyvid, an experimental imaging agent to detect signs of Alzheimer’s disease in the brain,
shouldn’t be approved because of unreliable study results, a consumer-advocacy group said.
MoreTwo wins to bring Lilly modest sales
May 9, 2011
J.K. WallFinally, some new revenue. Eli Lilly and Co. will enjoy modest new sales later this year after U.S. regulators approved a
new diabetes drug developed by a partner company, and another company nears approval on a drug that will produce royalties
for the Indianapolis-based drugmaker.
MoreFDA OKs new diabetes pill from Lilly, Boehringer
May 2, 2011
IBJ Staff and Associated PressThe Food and Drug Administration says it has approved a new diabetes pill from Boehringer Ingelheim and Eli Lilly for patients
who can't control their blood sugar with older medicines.
MoreLilly teams with Medtronic on Parkinson's treatment
April 26, 2011
J.K. WallEli Lilly and Co. plans to use an implantable drug-delivery system made by Medtronic Inc. to precisely target patients'
brains with an experimental drug for Parkinson’s disease.
MoreWellfount nabs $6M in venture capital
April 19, 2011
The Indianapolis-based institutional pharmacy, which serves long-term-care facilities, wants to expand its business nationally.
MoreAnalysts demand news on next Lilly blockbuster
April 18, 2011
J.K. WallEli Lilly and Co. spends a lot of time these days telling the rest of the story—how well it’s doing in areas not
connected to highly lucrative drugs about to see their patents expire. But for the most part, investors and analysts just
want to know when the next blockbuster will be coming.
MoreFDA wants further testing of Lilly pancreas drug
April 16, 2011
Associated PressEli Lilly and Co. Inc. said Friday that the FDA has asked the drugmaker to conduct another clinical trial of its proposed
pancreas drug before it resubmits an application to have the drug approved for sale.
MoreFeds: CVS to pay $17.5M over inflated Rx claims
April 15, 2011
Associated PressThe U.S. Justice Department says CVS Pharmacy Inc. has agreed to pay $17.5 million to settle allegations it overcharged Medicaid
programs in 10 states, including Indiana.
MoreLilly’s Bydureon wins backing of European drug panel
April 15, 2011
Bloomberg NewsThe drug awaits final action by the European Commission, which has the authority to approve medicines for the European Union.
The Commission usually makes a decision on CHMP recommendations within two to three months.
MoreChina making big gains in drug R&D jobs state covets
April 9, 2011
Greg AndrewsThe total annual cost for one researcher at Lilly might run $300,000 to $350,000 a year. The figure at Crown Bioscience is
one-third of that, said a company executive.
MoreAntidepressants linked to narrowed arteries
April 4, 2011
The study included Eli Lilly and Co. drug Cymbalta, which racked up sales of $3.5 billion last year for the Indianapolis-based
drugmaker.
MoreIndiana college to break ground on pharmacy school
April 1, 2011
IBJ Staff and Associated PressNorthern Indiana's Manchester College plans to begin work this summer on the college's new $18 million pharmacy school.
MoreDemographic shift steers Lilly's Asian operations
March 26, 2011
Greg AndrewsChina remains a small market for Eli Lilly and Co. It generated $320 million in sales for the company in 2010, just 1.3 percent
of its $23 billion in sales worldwide. But Lilly has big ambitions in China and is racing to capitalize on its rapid economic
growth.
MoreRegulators delay approval of Lilly's Alzheimer’s screen
March 18, 2011
Bloomberg NewsThe Food and Drug Administration said Lilly needs to create a training program to ensure brain scans are interpreted properly.
MoreTrade agency to probe Lilly's infringement claim
March 17, 2011
Bloomberg NewsEli Lilly and Co.’s patent-infringement claim over Hospira Inc.’s generic version of the cancer treatment Gemzar will be investigated
by a U.S. trade agency with the power to block imports of the copycat drug.
MoreLechleiter: After the deluge, we'll be fine
March 16, 2011
J.K. WallEli Lilly and Co. CEO John Lechleiter visited Japan last week—three days before the massive earthquake—to deliver
his tried-and-true message: Drug companies need to reinvent invention, governments needs to support innovation, and Lilly
will be just fine after it has sustained the damage of the next three years.
MoreLilly suffers another bruise from Novo
March 9, 2011
J.K. WallThe failure of its drug Bydureon to match the performance of Novo’s Victoza trims but doesn’t kill sales prospects for the
highly touted diabetes drug.
More
Sponsored by
ADVERTISEMENT
on Facebook & Twitter
on Facebook & Twitter
 Follow IBJ's Tweets on these topics: |
||
| @IBJNews | @Propertylines | @IBJTheScore |
| @IBJArts | @IBJHealthcare | @IBJDining |
| @IBJLists | @IBJSmallbiz | |
ADVERTISEMENT
Back to TopCopyright © All Rights Reserved. Privacy Policy | Terms of Use.
Design, CMS, Hosting & Web Development :: ePublishing.
Additional Hosting & Delivery by
RKW's comments read like a modern "Chicken Little". As a Raintree resident for many years, "Yes, I'm ready for this." Matter of fact, I welcome The Farm because it's a development that compliments our town, brings new and desirable shopping & dining closer (specialty grocer, upscale shops, micro brew pub, etc), offers upscale condos for empty nesters who want to stay in Zionsville, is being planned and constructed by local, well-reputed firms and, of course, provides desirable non property tax benefits. We all knew the Pittman's were going to develop their property sooner than later. That one of the Pittman's will continue to live on the property helps assure The Farm will be everything promised. This also sets a standard for other developers as to the quality of future developments - which should keep an ugly Walmart at bay for decades. As we've no meglomaniac mayor, I seriously doubt Zionsville would ever aspire to over-priced statues or subsidized retail rents. And we already have a very nice public theater, the Zionsville Performing Arts Center, that meets our cultural needs quite nicely.
Do we add (or subtract) these from the bounty we recieve from RTWFL, Daylight Savings Time, corporate tax giveaways, and the crack job IEDC is doing?? Or is Mike going to blame these on Mitch?
Who makes Tater Tots? They would be a good sponsor, because $3 Million for the alleged "Greatest Spectacle In Racing" is taters. Tiny, tiny taters. But at least they are making up something of the losses accumulated over the years in this dying sport. Buttock in seat is certainly not doing it, nor eyeball on TV, as evidenced by the lack of both.
We loved lakehouse and think the Arbor Village would be a great location. It is less than 2 miles from over 1000 rooftops in the 225,000 to over 1 million range. Many people could use the great fishers trail system to bike or walk there. Just an idea Scotty -- but maybe something closer to 3 Wiseman would good. The only microbrew in area is Ram (boring)
True, it's an ESPN production, but ESPN is just another name for ABC Sports, or what used to be ABC Sports since ABC Sports no longer exists as a name. ESPN=ABC Sports= ESPN. ESPN is, according to Forbes "the world's most valuable media property" worth $40 billion. Despite that, they fired 400 people this week.